Company intelligence / Profile preview
JIXING
Shanghai, Shanghai, Chinajixing.com ↗
- Ownership
- Private
- Employees
- ~210
- Development stage
- Other
01
Overview
JIXING's recent clinical progress includes acquisition of global rights to PB6440 (aldosterone synthase inhibitor for hypertension), with ongoing development in cardiovascular and ophthalmology indications; as of 2022-2024, pipeline comprises 7 assets in preclinical and clinical stages focused on China and global markets
- Therapeutic areas
- OphthalmologyCardiovascular
- Modalities
- Small moleculeMonoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CytokineticsMilestoneLENZ TherapeuticsOyster Pharma
Beyond the preview
Go deeper on JIXING.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JIXING.